Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

R. Land, Stephanie; Lawrence Wickerham, D.; P. Costantino, Joseph; W. Ritter, Marcie; G. Vogel, Victor; Lee, Myoungkeun; R. Pajon, Eduardo; L. Wade, James; R. Dakhil, Shaker; B. Lockhart, James; Wolmark, Norman; A. Ganz, Patricia

doi:10.1097/01.ogx.0000238649.97517.22

Public

Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

Published in Obstetrical & Gynecological Survey • Sep 18, 2006

Authors:

Stephanie R. Land

D. Lawrence Wickerham

Joseph P. Costantino

Abstract

The investigators assessed quality of life for 19,747 participants in a double-blind, randomized trial comparing tamoxifen (20 mg daily) and raloxifene (60 mg daily), both given for 5 years, for their ability to lower the risk of invasive breast cancer in postmenopausal women. Patients were followed...

Subject

Medicine

Tamoxifen

Raloxifene

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!